Market Place
Sourcing Support
EMD`s Biologic Bavencio (Avelumab) Receives Suppl Approval in US
11 Oct 2024 //
FDA
ASCO: Merck KGaA`s Bavencio combo misses survival mark in RCC
23 May 2024 //
FIERCE PHARMA
Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo
15 May 2024 //
BUSINESSWIRE
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line
22 Jan 2024 //
BUSINESSWIRE
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
13 Dec 2023 //
REUTERS
EMD Serono`s Biologic Bavencio (Avelumab) Receives Approval in the U.S.
06 Sep 2023 //
FDA
Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC
18 Aug 2023 //
ONCLIVE
Post-Hoc Analysis Confirms Safety of Maintenance Avelumab
03 Jul 2023 //
ONCLIVE
Positive Results from Interim Analysis of `GEN-001` Plus avelumab PII Trial
19 May 2023 //
PR NEWSWIRE
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
28 Mar 2023 //
ENDPTS
Merck KGaA Strengthens Oncology Franchise by Securing Rights to BAVENCIO
27 Mar 2023 //
BUSINESSWIRE
Analyses Reinforce Survival Benefit of BAVENCIO Treatment in Patients With UC
13 Feb 2023 //
BUSINESSWIRE
Promontory Therapeutics Presents Efficacy Data of PT-112 with PD-L1 Inhibition
08 Dec 2022 //
PRNEWSWIRE
Merck KGaA says Bavencio sales surge nearly 60% in Q3
10 Nov 2022 //
MERCKGROUP
Transgene Announces +ve Interim Analysis Results of PhII Trial Evaluating TG4001
02 Nov 2022 //
BUSINESSWIRE
4D pharma Presents Trial on Study of MRx0518 in Combination with BAVENCIO
26 May 2022 //
BUSINESSWIRE
NICE recommends avelumab for urothelial cancer patients
13 Apr 2022 //
PHARMAFILE
NICE overturns previous decision, recommends Merck and Pfizer’s Bavencio
11 Apr 2022 //
PHARMATIMES
Long-Term Follow-Up Data Reinforce Continued OS Benefit of BAVENCIO
18 Feb 2022 //
BUSINESSWIRE
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA
17 Nov 2021 //
GLOBENEWSWIRE
Merck KGaA`s healthcare sales rise 5.1% in Q3, led by Bavencio, Mavenclad
11 Nov 2021 //
FIRSTWORDPHARMA
University of Sheffield tests available drugs for incurable breast cancer
27 Sep 2021 //
CLINICALTRIALSARENA
Nektar Announces New Clinical Collaboration with Merck KGaA and Pfizer Inc.
21 Sep 2021 //
PRNEWSWIRE
Merck KGaA to Present Latest Highlights at WCLC and ESMO 2021
12 Sep 2021 //
NEWSWIRE
Aspirin as part of new treatment for aggressive form of breast cancer
17 Aug 2021 //
BREASTCANCERNOW
Scottish Medicines Consortium: August 2021 decisions news release
11 Aug 2021 //
PRESS RELEASE
Vaccinex to Enroll Patients in Studies of Pepinemab in Alzheimer’s Disease
08 Jun 2021 //
PRESS RELEASE
Avelumab not recommended as a maintenance treatment of urothelial cancer
06 May 2021 //
NICE
Preliminary NICE `no` for Merck`s Bavencio
05 May 2021 //
PHARMATIMES
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001
10 Mar 2021 //
BUSINESSWIRE
Health Canada Approves BAVENCIO® for the Maintenance Treatment
11 Jan 2021 //
NEWSWIRE
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance
11 Dec 2020 //
PRESS RELEASE
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance
11 Dec 2020 //
PRNEWSWIRE
Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination avelumab
04 Dec 2020 //
BUSINESSWIRE
EMD Serono`s Biological Avelumab Receives Approval in US
13 Nov 2020 //
FDA
Transgene Presents E-Poster Results from the Phase 1b/2 Trial of TG4001
09 Nov 2020 //
BIOSPACE
Transgene Presents E-Poster Outlining Results from the Ph 1b/2 Trial of TG4001
09 Nov 2020 //
BUSINESSWIRE
Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001
27 Oct 2020 //
PRNEWSWIRE
Bavencio, Imbruvica among latest SMC decisions
13 Oct 2020 //
PHARMATIMES
BM`s Opdivo racks up GI cancer data for 2 potentially practice-changing FDA nods
22 Sep 2020 //
FIERCE PHARMA
No Improvement In Survival With Avelumab Added To Crt In Locally Advanced SCCHN
20 Sep 2020 //
ESMO
Immutep Reports Improving Results from INSIGHT-004 Trial
18 Sep 2020 //
GLOBENEWSWIRE
Bavencio Pivotal Ph III Javelin Bladder 100 Results Published In The NEJM
18 Sep 2020 //
PRESS RELEASE
Phosplatin Therapeutics Announces Results from PhI Study of PT-112 Plus Avelumab
18 Sep 2020 //
BIOSPACE
EMD Serono Advances Oncology Portfolio and Pipeline
13 Sep 2020 //
BIOSPACE
MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer
03 Sep 2020 //
PHARMAFILE
UK bladder cancer patients get early access to Bavencio
03 Sep 2020 //
PHARMATIMES
Avelumab with axitinib for untreated advanced renal cell carcinoma
03 Sep 2020 //
NICE
NICE green light for immunotherapy Bavencio
01 Sep 2020 //
PHARMATIMES
NKMax America Receives FDA Clearance to Amend its Current Monotherapy Trial
31 Aug 2020 //
GLOBENEWSWIRE
NICE Recommends BAVENCIO® (Avelumab) in Combination with Axitinib
31 Jul 2020 //
PRESS RELEASE
NICE backs Bavencio combo for kidney cancer
30 Jul 2020 //
PHARMA TIMES
Transgene Reports Results From Clinical Study of TG4001 in Combination Avelumab
22 Jul 2020 //
BUSINESSWIRE
New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio
02 Jul 2020 //
ENDPTS
US approves Bavencio for bladder cancer
30 Jun 2020 //
PHARMATIMES
Avelumab safe, effective for treatment of gestational trophoblastic tumors
01 Jun 2020 //
HEALIO
ASCO: Bavencio boosts survival post-chemo in bladder cancer
01 Jun 2020 //
PMLIVE
Pfizer, Merck KGaA`s Bavencio lines up for bladder cancer edge
29 May 2020 //
FIERCE PHARMA
Immunotherapy Potentially Curative in Rare Placenta Cancer
28 May 2020 //
MEDPAGETODAY
Avelumab Appears to be Effective in Preventing Relapse in Women With GTT
28 May 2020 //
CANCERNETWORK
